A US federal judge has ruled that Novo did not prove Lilly’s obesity drug ad campaign, which included claims of superiority, caused meaningful harm to Novo’s sales, according to BioPharma Dive. The decision means Novo’s request to block the ads was denied.
This case matters for pharma brand leaders as it shows the limits of legal action over competitor advertising. Courts may demand clear evidence of commercial harm before restricting rival marketing. Companies should assess how they substantiate claims of injury in future disputes.
